Tango Therapeutics, Inc. (TNGX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Tango Therapeutics, Inc. (TNGX) closed at USD 22.19 on 2026-10-14, a change of +184.9 % over the past year, with a market capitalization of USD 3.83B.

Tango Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Tango Therapeutics, Inc. key figures

Previous close

USD 22.19 (2026-10-14)

1-year change

+184.9 %

Market cap

USD 3.83B

Enterprise value

USD 2.85B

P/E ratio (trailing)

-26.09

P/E ratio (forward)

-13.47

EPS (trailing)

-0.87

EPS (forward)

-1.69

PEG ratio

n/a

Price to book

3.73

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

15.15

Employees

137

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Tango Therapeutics, Inc. and compare it with other stocks.